SCHEMBL4303534

SCHEMBL4303534

C=CCn1c(=O)c(C(=O)OCC)c(O)c2ccc(F)cc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.72
KDM4E B2RXH2 7/20 0.55
ALDH1A1 P00352 6/20 0.55
KMT2A Q03164 6/20 0.55
MEN1 O00255 5/20 0.55
HTT P42858 2/20 0.55
HPGD P15428 2/20 0.55
HSD17B10 Q99714 2/20 0.55
USP2 O75604 2/20 0.55
TSHR P16473 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.48
RECQL P46063 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11377907 0.84 LMNA (0.71) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11376328 0.84 LMNA (1.00) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11374384 0.82 LMNA (0.69) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11393959 0.81 LMNA (0.67) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL25170075 0.80 LMNA (0.55) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL10803742 0.80 LMNA (0.71) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11385764 0.80 LMNA (0.65) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL10802134 0.79 LMNA (0.70) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11377719 0.79 LMNA (0.64) LMNAKDM4EALDH1A1KMT2AMEN1
SCHEMBL11381445 0.79 LMNA (0.64) LMNAKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071592-B2 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1992628-A1 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2008-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES ETFA, NQO2, GNAQ LMNA 905/4885KDM4E 2078/4885ALDH1A1 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.